Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.

The potential stability of pyrilutamide in a mixture with water, and how it could be used in combination with Minoxidil and Finasteride to treat hair loss.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.

The conversation is about making topical finasteride with stemoxydine, including questions on dosages, bulk preparation, and storage.

Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.

User asks if mixing RU58841 solution with Serioxyl is okay for better scalp coverage and worries about reduced effects.

RU58841 should be stored in the refrigerator to maintain efficacy, but it remains stable for over two years even without refrigeration. A user prefers using Minoxidil and finasteride instead.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation discusses the best vehicle for topical dutasteride, comparing Trichosol, Transcutol, and a gel version. It also mentions using Transcutol with ethanol to enhance transdermal delivery of Bimatoprost.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

A user wants to make a solution for RU58841 and finasteride powder using only glycerin and asks if ethanol is necessary. They are seeking advice on whether glycerin alone is sufficient.

Users discuss making topical finasteride solutions by dissolving crushed tablets in ethanol and propylene glycol, with concerns about residue affecting effectiveness. They also mention using minoxidil and oral finasteride, noting some hair regrowth and no side effects from topical use.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses creating a customized minoxidil formulation with tretinoin, azelaic acid, and caffeine, but there are concerns about foam stabilization due to acidity. The user seeks advice on the best formulation for effective results.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

Store finasteride powder in a cool, dry place. RU58841 needs to be stored in the freezer.

Crushing finasteride pills into stemoxydine may not be effective without removing the coating first. It's unclear if the pills dissolve completely or settle as sediment.

Taking dutasteride with a meal containing fat may improve absorption, but consistency in routine is more important than timing. Minor variations in absorption won't significantly affect efficacy due to dutasteride's long half-life.